Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage biotech company advancing tumor-agnostic therapies targeting oncogenic mutations in cancers like NSCLC and glioblastoma. This page provides investors and researchers with essential updates on the company’s precision oncology developments.
Find consolidated access to press releases, clinical trial data, and regulatory milestones for BDTX’s pipeline, including MasterKey therapies BDTX-1535 (EGFR inhibitor) and BDTX-4933. Track progress on mutation-targeted approaches addressing resistance mechanisms like the C797S mutation in EGFR.
Our news collection serves as a reliable resource for monitoring strategic partnerships, research publications, and FDA communications related to the company’s Mutation-Allostery-Pharmacology platform. Content is curated to help stakeholders assess scientific progress without promotional bias.
Bookmark this page for streamlined updates on Black Diamond’s efforts to expand treatment options in precision oncology. Check regularly for new developments in small-molecule kinase inhibitors and tumor-agnostic therapeutic strategies.
Black Diamond Therapeutics (BDTX), a clinical-stage oncology company focused on developing MasterKey therapies for cancer patients, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Mark Velleca will engage in a fireside chat on June 4, 2025 from 4:20-4:50pm ET in New York. The company will also conduct one-on-one investor meetings during the event. A webcast of the presentation will be accessible through Black Diamond's website and remain archived for 90 days post-event.
Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company specializing in MasterKey therapies for cancer treatment, has announced its upcoming participation in two major investor conferences.
The company's President and CEO, Mark Velleca, M.D., Ph.D., will present at the following events:
- 24th Annual Needham Virtual Healthcare Conference - April 7, 2025, at 3:00 PM ET
- Stifel 2025 Virtual Targeted Oncology Forum - April 8, 2025, at 1:00 PM ET
Both presentations will be accessible via webcast on the investor relations section of Black Diamond Therapeutics' website, with replays available for 90 days.
Servier and Black Diamond Therapeutics (BDTX) have entered into a global licensing agreement for BDTX-4933, a Phase 1 targeted oncology therapy. The deal includes a $70 million upfront payment to Black Diamond, with potential additional payments of up to $710 million in development and commercial milestones, plus tiered royalties.
BDTX-4933 is designed as a potential best-in-class treatment targeting both RAS mutations and RAF alterations in solid tumors, including non-small cell lung cancer (NSCLC). The drug is currently in Phase 1 development, evaluating safety, tolerability, and antitumor activity in patients with recurrent advanced/metastatic cancers harboring BRAF, CRAF, or NRAS mutations.
Under the agreement, Servier will lead global development activities and commercialization of BDTX-4933 across multiple indications.
Black Diamond Therapeutics (BDTX) has reported its Q4 and full year 2024 financial results. The company ended 2024 with $98.6 million in cash and equivalents, projected to fund operations into Q4 2026. Net loss for Q4 2024 was $16.0 million, improved from $19.4 million in Q4 2023.
Key developments include anticipated Phase 2 clinical data for BDTX-1535 in Q2 2025 for first-line non-classical EGFRm NSCLC patients. The company plans to expand its 'window of opportunity' trial into newly diagnosed glioblastoma patients with EGFR aberrations in Q1 2025.
Financial metrics show R&D expenses decreased to $51.3 million in 2024 from $59.4 million in 2023, while G&A expenses slightly increased to $27.5 million from $27.1 million. Full-year net loss improved to $69.7 million compared to $82.4 million in 2023.
Black Diamond Therapeutics (BDTX) reported Q3 2024 financial results and corporate updates. The company announced encouraging Phase 2 data for BDTX-1535 in NSCLC patients, showing a 42% overall response rate in 19 patients with osimertinib resistance mutations. Cash position stood at $112.7 million as of September 30, 2024, expected to fund operations into Q2 2026. Q3 net loss improved to $15.6 million from $23.0 million year-over-year. The company implemented a corporate restructuring, deprioritizing BDTX-4933 to focus on BDTX-1535 development. Clinical updates and regulatory feedback are expected in Q1 2025.
Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies for cancer treatments, announced its upcoming participation in two major investor conferences. President and CEO Mark Velleca will present at the Stifel Healthcare Conference on November 19, 2024, at 4:10pm ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:00pm ET. Webcasts will be available on the company's website and archived for 90 days.
Black Diamond Therapeutics (Nasdaq: BDTX) announced a corporate restructuring to focus resources on advancing its lead program BDTX-1535 into pivotal development for EGFRm NSCLC. The company aims to extend its cash runway into Q2 2026. Key points include:
- Anticipates sharing initial Phase 2 data for BDTX-1535 in the frontline setting for EGFRm NSCLC in Q1 2025
- Plans to present updated Phase 2 results for BDTX-1535 in recurrent EGFRm NSCLC in Q1 2025
- Deprioritizing BDTX-4933 program and seeking potential partners
- Implementing a reduction in force while retaining core expertise
- Chief Business Officer, CFO, and Chief People Officer departing; Erika Jones appointed as Principal Financial Officer
The restructuring aims to optimize operations and focus investment on BDTX-1535, which has shown robust Phase 2 clinical activity in recurrent NSCLC patients with EGFR mutations.
Black Diamond Therapeutics has reported promising initial Phase 2 data for BDTX-1535 in patients with recurrent EGFRm NSCLC. Key findings include:
- A 200 mg daily dose selected for pivotal development, showing a favorable tolerability profile
- Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations
- Encouraging durability with DOR of approximately 8 months or more for the first 3 patients with a PR
- 14 of 19 patients remain on treatment
The company anticipates regulatory feedback on the registration path in Q1 2025 and expects initial results of BDTX-1535 in first-line NSCLC patients with non-classical EGFR mutations in the same quarter.
Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company, has announced a webcast presentation of initial Phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC. The webcast is scheduled for Monday, September 23, 2024, at 8:00 a.m. ET.
Black Diamond specializes in developing MasterKey therapies targeting families of oncogenic mutations in cancer patients. The presentation will be accessible under the 'Events and Presentations' section of the company's website, with a replay available after the event.
FAQ
What is the current stock price of Black Diamond Therapeutics (BDTX)?
What is the market cap of Black Diamond Therapeutics (BDTX)?
